Published in Gene Therapy Weekly, December 18th, 2003
Since target selection is of paramount importance in antisense drug development, these studies demonstrate AVI's progress in validating prostate cancer targets. Results were published in the peer-reviewed journals Cancer Gene Therapy and Clinical Cancer Research.
"These two studies demonstrate AVI's commitment to developing antisense drugs for the potential treatment of cancer," said Patrick L. Iversen, senior vice president of research and development at AVI. "We are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.